RPG Life Sciences Reports Q2 FY26 Results: Standalone Profit Rises to 3,057 Lakhs; Consolidated Income Reaches 3,061 Lakhs
RPG Life Sciences Limited has released its unaudited financial results for the quarter ended June 30, 2026. The company reported a profit of 3,057 lakh in its standalone results and consolidated income of 3,061 lakh across the group, reflecting operations primarily within the Pharmaceuticals segment.The Company’s Board of Directors unanimously approved these financial results at a meeting held on July 28, 2026. The results were reviewed by the Audit Committee.
Standalone Financial Highlights (Q ended June 30, 2026)
Standalone figures show that Revenue from Operations stood at 19,569 lakh for the quarter ending June 30, 2026. Total Income was reported at 19,985 lakh. The company recorded total expenses of 15,864 lakh. Profit before tax was 4,121 lakh, leading to a profit for the period of 3,057 lakh.The earnings per share (EPS) for both basic and diluted calculations was reported at 18.49 in Rupees per share.
Key financial data from the standalone results are summarized below:
| Financial Metric | Q ended 30-06-2026 (Unaudited) | Quarter ended 31-03-2026 (Audited) | Q ended 30-06-2025 (Unaudited) | Year ended 31-03-2026 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 19,569 | 17,689 | 16,892 | 70,752 |
| Other Income | 416 | 1,236 | 523 | 2,554 |
| Total Income | 19,985 | 18,925 | 17,415 | 73,306 |
| Total Expenses | 15,864 | 15,015 | 13,872 | 58,276 |
| Profit before tax | 4,121 | 4,020 | 3,543 | 15,420 |
| Total Tax Expenses | 1,064 | 1,030 | 914 | 3,903 |
| Profit for the Period | 3,057 | 2,990 | 2,629 | 11,517 |
Consolidated Financial Performance (Q ended June 30, 2026)
The consolidated results of RPG Life Sciences Limited and its subsidiary, RPG Active Pharma Limited, reflect a Total Income of 20,039 lakh for the quarter ending June 30, 2026. With total expenses reported at 15,893 lakh, the company registered a profit for the period of 3,076 lakh.Total Comprehensive Income for the group stood at 3,061 lakh, and Earnings Per Share (EPS) was recorded at 18.60 in Rupees per share.
The table below presents the key consolidated figures:
| Financial Metric | Q ended 30-06-2026 (Unaudited) | Quarter ended 31-03-2026 (Audited) | Q ended 30-06-2025 (Unaudited) | Year ended 31-03-2026 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 19,569 | 17,689 | 16,892 | 70,752 |
| Other Income | 470 | 1,240 | 523 | 2,558 |
| Total Income | 20,039 | 18,929 | 17,415 | 73,310 |
| Total Expenses | 15,893 | 15,019 | 13,872 | 58,280 |
| Profit before tax | 4,146 | 4,020 | 3,543 | 15,420 |
| Total Tax Expenses | 1,070 | 1,030 | 914 | 3,903 |
| Profit for the Period | 3,076 | 2,990 | 2,629 | 11,517 |
Exceptional Items and Operational Notes
Both standalone and consolidated results noted exceptional items during the financial year ended March 31, 2026. These included:- Insurance Claim: The group recognized a net income of Rs 2,475 lakhs related to the settlement of an insurance claim arising from a fire incident at its Navi Mumbai API plant that occurred in January 2025.
- Other Income: An additional compensation of Rs 791 lakhs for business interruption losses was recorded as Other Income during the quarter ended March 31, 2026.
- Labour Codes Expense: A net exceptional expense of Rs 1,169 lakhs was recognized towards the impact of new Labour Codes notified effective November 22, 2025, primarily due to changes in wage definition.
- Intangible Asset Impairment: An intangible asset under development was written off and recognized as an exceptional item after management's annual assessment indicated no future economic benefits were expected from the project.
RPGLIFE Stock Price Movement
Shares of RPG Life Sciences Limited today slipped, settling at ₹2888.7 after shedding 1.81% during the trading session. The stock saw movement within a tight intraday range between a high of ₹2924.6 and a low of ₹2850, as 8,327 shares changed hands.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: